Head and Neck Cancer Clinical Trial
Official title:
A Phase I Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 With Concurrent Cisplatin and Radiation Therapy in Subjects With Locally Advanced Head and Neck Cancer
Verified date | February 2018 |
Source | Curis, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase I dose escalation study of CUDC-101 in combination with concurrent cisplatin and radiation therapy in patients with locally advanced head and neck cancer. CUDC-101 is a multi-targeted agent designed to inhibit epidermal growth factor receptor (EGFR), human epidermal growth factor receptor Type 2 (Her2) and histone deacetylase (HDAC). The study is designed to establish the safety, tolerability and maximum tolerated dose (MTD) of CUDC-101 when administered in combination with concurrent cisplatin and radiation over an 8-week treatment course, consisting of a one week run-in period of CUDC-101 administered alone, followed by seven weeks of combination treatment with CUDC-101, cisplatin and radiation therapy.
Status | Completed |
Enrollment | 12 |
Est. completion date | October 2013 |
Est. primary completion date | September 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Subjects with locally advanced, pathologically confirmed diagnosis of squamous cell carcinoma of the head and neck at the following sites: oral cavity, oropharynx, hypopharynx and larynx with either: - Stage IV p16 positive tumors and >10 pack-years smoking history. - Stage III/IV p16 negative tumors, regardless of smoking history. - At least evaluable disease; one measurable site of disease according to RECIST (Version 1.1) criteria (at least 10 mm for conventional CT/MRI or spiral CT scan) is desirable. - Subjects enrolled in the MTD expansion cohort must have at least 1 tumor lesion that is suitable for repeat biopsy (pre- and post-CUDC-101 infusion). - Age = 18 years - ECOG performance < 2 - Life expectancy = 3 months - If female, neither pregnant nor lactating - If of child bearing potential, must use adequate birth control throughout the participation in the treatment phase and for 60 days following the last study treatment. - Absolute neutrophil count = 1,800/µL; platelets = 100,000/µL; hemoglobin = 8.0 g/dL, creatinine = 1.5x upper limit of normal (ULN); total bilirubin = 1.5x ULN; AST/ALT = 2 x ULN. - Serum magnesium and potassium within normal limits (may be supplemented to achieve normal values) - Able to render informed consent and to follow protocol requirements. Exclusion Criteria: - Prior radiotherapy to the region of the study cancer or adjacent anatomical sites, or > 25% of marrow-bearing area. - Prior chemotherapy for the current indication. - Prior therapy that specifically and directly targets EGFR, HER2 or HDAC. - Use of investigational agent(s) within 30 days prior to study treatment. - Primary tumor site of nasopharynx, sinuses, or salivary gland. - History of cardiac disease with a New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF), myocardial infarction (MI) or unstable angina in the past 6 months prior to Day 1 of treatment, serious arrhythmias requiring medication for treatment. - Patients with prolonged QTc Interval >450 msec. - Acquired Immune Deficiency Syndrome (AIDS) or known infection with human immunodeficiency virus (HIV). Testing is not required. - Known history of gastrointestinal bleeding, ulceration, or perforation within 6 months prior to study treatment. - Known history of stroke or cerebrovascular accident within 6 months prior to study treatment. - Symptomatic cardiac conduction abnormality within 12 months prior to study treatment. - Prior history of hearing impairment. - Known history of renal disease or ongoing renal impairment. - Any uncontrolled condition (such as active systemic infection, diabetes, hypertension), which in the opinion of the investigator, could affect the subjects participation in the study. - Prior allergic reaction to cisplatin, carboplatin or other platinum-containing compounds. - Central nervous system metastases. |
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado Cancer Center | Aurora | Colorado |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Vanderbilt University | Nashville | Tennessee |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Overton Brooks VA Medical Center | Shreveport | Louisiana |
United States | Stanford Cancer Center | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Curis, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The number of participants with adverse events. | Safety and tolerability will be assessed by evaluating the number of patients with adverse events | 18-24 months | |
Secondary | The number of subjects disease free at the completion of the treatment period. | To evaluate the efficacy of CUDC-101 in combination with cisplatin and radiation therapy by evaluating the number of subjects disease free at the completion of the treatment period. | 18-24 months | |
Secondary | The number of subjects disease free in the follow up period. | To evaluate the efficacy of CUDC-101 in combination with cisplatin and radiation therapy by evaluating the number of subjects disease free in the follow up period. | 18-24 months | |
Secondary | Concentration of CUDC-101 in the blood over time. | Pharmacokinetics will involve a determination of the concentration of CUDC-101 in the blood over time. | 18-24 months | |
Secondary | Number of circulating tumor cells pre treatment on Day -7 and 1 hour post treatment on Day -3. | The ability of CUDC-101 to exert a biological effect on the tumor will be examined in pharmacodynamic samples. | 18-24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |